Saudi Heart Association Position Statement on Troponin use for Cardiovascular Risk Screening in Asymptomatic Populations

Background Cardiovascular disease (CVD) remains the leading cause of death and disability globally. In Saudi Arabia, the burden of CVD is exceptionally high, with age-standardized mortality and prevalence rates that far exceed global averages. The current CVD risk prediction tools have several limitations, and those classified as low to intermediate risk still experience cardiovascular events, underscoring the urgent need to address CVD through effective screening and prevention strategies. Methods A panel of Saudi experts reviewed evidence on the use of high-sensitivity cardiac troponin (hs-cTn) to enhance cardiovascular risk assessment among seemingly healthy individuals. Consensus recommendations tailored to the Saudi context were formulated based on the literature and local clinical practice, taking into consideration the characteristics of the Saudi population, local healthcare system, available resources and medical expertise. Results and conclusion Cardiac troponins are biomarkers of myocardial injury that can be detected in most seemingly healthy individuals using high-sensitivity assays. Studies have shown that measuring hs-cTn is a reliable predictor of future cardiovascular events in the general population. Consequently, incorporating hs-cTn into cardiovascular risk assessments could significantly improve the accuracy and effectiveness of existing risk stratification models. The experts highlighted the additional benefits of this approach compared to current risk assessment methods. This document aims to guide the integration of hs-cTn into cardiovascular risk assessment and prevention strategies for seemingly healthy individuals.

• Publication year

  2025

• Venue

  Journal of the Saudi Heart Association

• Publication date

  2025-07-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.37616/2212-5043.1444PMID 40792060PMCID 12339041
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A national perspective on cardiovascular diseases in Saudi Arabia

  2024cited by this paper
• Major Limitations of Cardiovascular Risk Scores

  2024cited by this paper
• Cost-effectiveness of applying high-sensitivity troponin I to a score for cardiovascular risk prediction in asymptomatic population

  2024cited by this paper
• A cost-effectiveness evaluation of a high-sensitivity troponin I guided voluntary cardiovascular risk assessment program for asymptomatic women in Croatia

  2024cited by this paper
• Global Burden of Cardiovascular Diseases and Risks, 1990-2022.

  2023cited by this paper
• Cardiovascular Disease in Saudi Arabia: Facts and the Way Forward

  2023cited by this paper
• Development and Validation of the American Heart Association’s PREVENT Equations

  2023cited by this paper
• SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe

  2023cited by this paper
• Optimizing the Clinical Use of High-Sensitivity Troponin Assays: A Review

  2023cited by this paper
• A Heart-Healthy and Stroke-Free World: Using Data to Inform Global Action.

  2023cited by this paper
• High sensitivity troponins: A potential biomarkers of cardiovascular risk for primary prevention

  2022cited by this paper
• Metabolic Pathway of Cardiac Troponins and Its Diagnostic Value

  2022influential reference
• Summary of Global Burden of Disease Study Methods.

  2022cited by this paper
• The Metabolic Pathway of Cardiac Troponins Release: Mechanisms and Diagnostic Role

  2022influential reference
• SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.

  2021cited by this paper
• Cardiac Troponins: Contemporary Biological Data and New Methods of Determination

  2021cited by this paper
• Estimating the cost-effectiveness of screening a general population for cardiovascular risk with high-sensitivity troponin-I

  2021cited by this paper
• 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

  2021cited by this paper
• Troponin Variants as Markers of Skeletal Muscle Health and Diseases

  2021cited by this paper
• Comorbidity in chronic obstructive pulmonary disease and cardiovascular disease

  2021cited by this paper
• SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.

  2021cited by this paper
• Demographic, behavioral, and cardiovascular disease risk factors in the Saudi population: results from the Prospective Urban Rural Epidemiology study (PURE-Saudi)

  2020cited by this paper
• A Comparison of Four Cardiovascular Risk Assessment Instruments in Saudi Patients

  2020influential reference
• High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population.

  2020cited by this paper
• 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

  2020cited by this paper
• Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers

  2020cited by this paper
• Machine learning to predict cardiovascular risk

  2019cited by this paper
• Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews

  2019cited by this paper
• Cardiac Troponin T and Troponin I in the General Population

  2019cited by this paper
• [Clinical and Diagnostic Value of Cardiac Markers in Human Biological Fluids].

  2019cited by this paper
• Interpreting troponin in renal disease: A narrative review for emergency clinicians.

  2019cited by this paper
• High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.

  2019cited by this paper
• Fourth Universal Definition of Myocardial Infarction (2018).

  2018cited by this paper
• Relative Prognostic Value of Cardiac Troponin I and C-Reactive Protein in the General Population (from the Nord-Trøndelag Health [HUNT] Study).

  2018cited by this paper
• How is cardiac troponin released from injured myocardium?

  2018cited by this paper
• Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk

  2018cited by this paper
• Fourth Universal Definition of Myocardial Infarction (2018).

  2018cited by this paper
• Implementation of High-Sensitivity Cardiac Troponin: Challenges From the International Experience

  2018cited by this paper
• What to do when you question cardiac troponin values

  2018cited by this paper
• Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses

  2017cited by this paper
• High-sensitivity cardiac troponin assays: From improved analytical performance to enhanced risk stratification

  2017cited by this paper
• Prognostic Value of New‐Generation Troponins in ST‐Segment–Elevation Myocardial Infarction in the Modern Era: The RUTI‐STEMI Study

  2017cited by this paper
• Renal Dysfunction Influences the Diagnostic and Prognostic Performance of High-Sensitivity Cardiac Troponin I.

  2017cited by this paper
• High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants

  2017cited by this paper
• High-sensitivity cardiac troponin I and risk of cardiovascular disease in an Australianpopulation-based cohort

  2017cited by this paper
• Acute Myocardial Response to Stretch: What We (don't) Know

  2016cited by this paper
• Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium

  2016influential reference
• High-Sensitivity Cardiac Troponin I Is a Strong Predictor of Cardiovascular Events and Mortality in the AGES-Reykjavik Community-Based Cohort of Older Individuals.

  2016cited by this paper
• High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease

  2016cited by this paper
• An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort.

  2015cited by this paper
• High-Sensitivity Cardiac Troponin I and B-Type Natriuretic Peptide as Predictors of Vascular Events in Primary Prevention

  2015cited by this paper
• High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort.

  2014cited by this paper
• Cardiac troponin in ischemic cardiomyocytes: intracellular decrease before onset of cell death.

  2014cited by this paper
• Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction.

  2013cited by this paper
• Troponin release--reversible or irreversible injury? Should we care?

  2012cited by this paper
• Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease.

  2012cited by this paper
• ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

  2011cited by this paper
• Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis?

  2011cited by this paper
• [Relative validity of the 10-year cardiovascular risk estimate in a population cohort of the REGICOR study].

  2011cited by this paper
• Cardiac troponin may be released by ischemia alone, without necrosis.

  2010cited by this paper
• Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.

  2010influential reference
• General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study

  2008cited by this paper
• Evidence for Cardiomyocyte Renewal in Humans

  2008cited by this paper
• Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality

  2007cited by this paper
• Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation

  2007cited by this paper
• National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes.

  2007cited by this paper
• Prevalence and Determinants of Troponin T Elevation in the General Population

  2006cited by this paper
• Partial and delayed release of troponin-I compared with the release of lactate dehydrogenase from necrotic cardiomyocytes

  2004cited by this paper
• A heart-healthy and "stroke-free" world through policy development, systems change, and environmental supports: a 2020 vision for sub-Saharan Africa.

  2003influential reference
• Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure

  2003cited by this paper
• Preload Induces Troponin I Degradation Independently of Myocardial Ischemia

  2001cited by this paper
• The regulation of contractile activity in muscle.

  1979cited by this paper

• No citing papers are available for this paper.